Power Prenatal Supplements for Sperm Quality

Sponsor
The Bird and Be Co Inc (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05410782
Collaborator
(none)
50
1
6.5

Study Details

Study Description

Brief Summary

Male factor infertility is a leading cause of primary and secondary infertility. Poor sperm quality is defined as having an abnormal semen analysis [WHO 2020 - https://www.who.int/publications/i/item/9789240030787]. The effects of supplements (vitamins, minerals, and anti-oxidants) on improving sperm quality are still debated (https://pubmed.ncbi.nlm.nih.gov/30462179). Taking additional supplements to improve sperm quality represent a modifiable risk-factor that would be an easy intervention for patients struggling with male factor infertility. The life cycle of sperm production is estimated at 3 months, so any intervention would require a 3 month course to see its full effect.

We hypothesize that a 90 day course of the "Power Prenatal for Sperm", a male fertility supplement by Bird&Be (https://birdandbe.com/the-power-prenatal-for-sperm) will improve sperm quality based on semen analysis results prior to, and after taking the supplements.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Power Prenatal for Sperm
N/A

Detailed Description

Male patients presenting to Conceive Health (https://conceivehealth.com/) for infertility care will be potential candidates for this study. Male patients that have had a recent abnormal semen analysis conforming at least 1 of 3 parameters (low concentration: < 15 Million / mL; low progressive motility < 30%, and low morphology with strict criteria < 4%) will be eligible to participate.

Patients will be approached by a study coordinator to participate in the study. The study coordinator will ensure all inclusion and exclusion criteria is met, consents forms are signed, and a 90 day course of the "Power Prenatal for Sperm" is dispensed

Study participants will be instructed to repeat a semen analysis (at the same lab) after their 90 day course of the "Power Prenatal for Sperm". The differences between the semen analysis parameters will be compared

The primary outcome was chosen as processive motility, as this parameter is mostly likely to be positively impacted by the Power Prenatal for Sperm.

An abnormal progressive motility is defined as <5th percentile (32%) of the semen analysis of the fertile male population. The standard deviation for this population is 13.5%. The estimated effect size is 37.5%, from 32% to 44%, an increase of 12%. The alpha (type 1 error) significant level was set at 5% and the power level was set at 80%. The required sample size was 40 patients. Given that this study requires a 3 month intervention prior to a follow up semen analysis for comparison, we estimated a 20% drop-out rate, so the total requirement was set at 50 patients.

Table A1.2 (https://www.who.int/docs/default-source/reproductive-health/srhr-documents/infertility/exami nation-and-processing-of-human-semen-5ed-eng.pdf)

Statistical analyses will be performed using standard expected methods. All data will be presented as mean ± Standard Deviation (SD). Statistical significance between semen analysis data will be determined by using the Shapiro-Wilk test of normality for predictions and paired samples t-test.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Patients with male factor infertility, who have a document abnormal semen analysis (at least 1 of 3 abnormal parameters - concentration, progressive motility or morphology) will be recruited to take a 3 month course of supplements (Power Prenatal for Sperm), and a repeat semen analysis will be performed after the intervention to compare resultsPatients with male factor infertility, who have a document abnormal semen analysis (at least 1 of 3 abnormal parameters - concentration, progressive motility or morphology) will be recruited to take a 3 month course of supplements (Power Prenatal for Sperm), and a repeat semen analysis will be performed after the intervention to compare results
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Three Month Course of Power Prenatal Supplements to Improve Sperm Quality in Male-factor Infertility Patients
Anticipated Study Start Date :
Jun 15, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Power Prenatal for Sperm

This is a single arm study. Participants will take supplements for 3 months. The supplements is Power Prenatal for Sperm (active ingredients - https://birdandbe.com/the-power-prenatal-for-sperm)

Dietary Supplement: Power Prenatal for Sperm
A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
Other Names:
  • Prenatal Vitamins
  • Outcome Measures

    Primary Outcome Measures

    1. Sperm Progressive Motility (Semen Analysis); as percentage (%) [A repeat semen analysis will be performed 3 months after Power Prenatal for Sperm intervention]

      Semen analysis

    Secondary Outcome Measures

    1. Sperm Concentration (Semen Analysis); as millions / mL [A repeat semen analysis will be performed 3 months after Power Prenatal for Sperm intervention]

      Semen analysis

    2. Sperm Morphology (Semen Analysis); as percentage (%) [A repeat semen analysis will be performed 3 months after Power Prenatal for Sperm intervention]

      Semen Analysis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Male

    • Age 18-45 years old

    • Experiencing infertility

    • A recent semen analysis confirming low count, motility or morphology (at least 1 of 3)

    • within last 3 months

    1. Low concentration: < 15 Million / mL

    2. Low Motility: Progessive Motility < 30%

    3. Morphology: Strict criteria: Normal forms < 4% Reference: WHO 2020 6th edition: https://www.who.int/publications/i/item/9789240030787

    Exclusion Criteria:
    • No diagnosed varicocele

    • Younger than 18 years old

    • Older than 45 years old

    • Currently taking any form of antioxidant supplements(in last 3 months) besides a general multivitamin

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • The Bird and Be Co Inc

    Investigators

    • Study Director: Dan Nayot, BSc, MSc, MD, The Bird and Be Co

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Bird and Be Co Inc
    ClinicalTrials.gov Identifier:
    NCT05410782
    Other Study ID Numbers:
    • Power Prenatal for Sperm
    First Posted:
    Jun 8, 2022
    Last Update Posted:
    Jun 8, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 8, 2022